Australia Immunosuppressant Drugs Market Size & Outlook
Related Markets
Australia immunosuppressant drugs market highlights
- The Australia immunosuppressant drugs market generated a revenue of USD 1,763.0 million in 2020 and is expected to reach USD 3,193.8 million by 2027.
- The Australia market is expected to grow at a CAGR of 8.9% from 2021 to 2027.
- In terms of segment, monoclonal antibodies was the largest revenue generating drug class in 2020.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Immunosuppressant drugs market data book summary
| Market revenue in 2020 | USD 1,763.0 million |
| Market revenue in 2027 | USD 3,193.8 million |
| Growth rate | 8.9% (CAGR from 2020 to 2027) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Calcineurin Inhibitors, MTOR Inhibitors, Antiproliferative Agents, Monoclonal Antibodies |
Other key industry trends
- In terms of revenue, Australia accounted for 1.8% of the global immunosuppressant drugs market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Asia Pacific, China immunosuppressant drugs market is projected to lead the regional market in terms of revenue in 2027.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,785.3 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunosuppressant Drugs Market Scope
Immunosuppressant Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| No records found. | ||||
Australia immunosuppressant drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunosuppressant drugs market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 72.6% in 2020. Horizon Databook has segmented the Australia immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
According to Australian Department of Health, dental health in Australia has improved over the last 25 to 30 years and changes such as adding fluoride to drinking water have helped to reduce tooth decay in children and adults.
Despite this, 3 out of 10 adults in the age from 22 to 44 years have untreated tooth decay and 3 in 10 people were observed to delay or avoid dental visit because of the cost, according to Australian Institute of Health and Welfare.
However Australian government is increasing funding dental services to improve oral health in Australia and has launched National Oral Health Plan 2015 to 2024 to provide more public dental services for adults. Moreover, cosmetic dentistry procedures in Australia have also witnessed a surge.
Reasons to subscribe to Australia immunosuppressant drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia immunosuppressant drugs market databook
-
Our clientele includes a mix of immunosuppressant drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia immunosuppressant drugs market, including forecasts for subscribers. This country databook contains high-level insights into Australia immunosuppressant drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
Australia immunosuppressant drugs market size, by drug class, 2016-2027 (US$M)
Australia Immunosuppressant Drugs Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
